Showing results (1-10 of 99) with videos related to
Sort By:
Pageof 10
Biologics : Targets & Therapy|August 27, 2009
Agalsidase alfa (Replagal) in the treatment of Anderson-Fabry diseaseGregory M PastoresExpert Opinion on Biological Therapy|June 14, 2008
Laronidase (Aldurazyme): enzyme replacement therapy for mucopolysaccharidosis type IGregory M PastoresRecent Patents on CNS Drug Discovery|January 29, 2008
Miglustat: substrate reduction therapy for lysosomal storage disorders associated with primary central nervous system involvementGregory M PastoresHandbook of Clinical Neurology|August 24, 2023
Lysosomal storage disorders: Clinical and therapeutic aspectsGregory M PastoresBest Practice & Research. Clinical Rheumatology|November 26, 2008
Musculoskeletal complications encountered in the lysosomal storage disordersGregory M PastoresContinuum (Minneapolis, Minn.)|July 20, 2012
Leukoencephalopathies and leukodystrophiesGregory M PastoresCurrent Opinion in Investigational Drugs (London, England : 2000)|March 26, 2010
Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher diseaseGregory M PastoresWiener Medizinische Wochenschrift (1946)|January 12, 2011
Neuropathic Gaucher diseaseGregory M PastoresExpert Review of Endocrinology & Metabolism|February 16, 2019
Velaglucerase alfa as a therapeutic option for Gaucher diseaseGregory M PastoresBiodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 9, 2010
Recombinant glucocerebrosidase (imiglucerase) as a therapy for Gaucher diseaseGregory M PastoresPageof 10